SmartBreast Corp

SmartBreast empowers women with dense breasts to defeat cancer through early detection and treatment. 1 of every 2 Western women (2 of every 3 Asian women) have dense breasts, which is a normal condition. Until recently, most women were never told about their breast density and the facts that 1) dense breasts increase the risk for cancer up to 5 times and 2) screening mammography fails 70% of the time in dense breasts! Because dense tissue and cancer are both white on X-ray mammograms, cancer can easily be hidden until it is large and late-stage, when treatment is severe (mastectomy, radiation, chemotherapy, 29% survival after 5 years). When breast cancer is found early, survival is 99% after 5 years - the cancer is cured! SmartBreast offers one of the best methods to find early-stage cancer in dense breasts, called "Molecular Breast Imaging" or simply "MBI." MBI uses 3 innovations to solve the dense-breast problem: 1) MBI uses a tracer molecule (Nobel prize discovery) that concentrates in tumor cells, 2) MBI uses gamma photons that safely pass through dense breast tissue, and 3) MBI uses specially designed solid-state gamma cameras (based on another Nobel prize) to image the tracer concentrations in the breast. There is a bonus benefit to MBI: unlike mammography, MBI is painless, only mildly immobilizing the breast. We analyzed 24 publications (meta-analysis) to discover that the Cancer Detection Rate (CDR) for Digital Mammography (DM) is 4 cancers for every 1,000 dense-breast women screened. Digital Breast Tomosynthesis (DBT or 3D DM) finds 5 cancers; ultrasound (U/S) finds 7. Three modalities (MBI, Contrast-Enhanced Mammography (CEM), and MRI) each find 14 cancers. This means that DM misses 10 (71%), DBT misses 9 (61%) and U/S misses 7 (49%)! MBI is FDA-cleared and reimbursed in most locations, including 12 countries. SmartBreast manufactures, sells, installs, and services MBI. Write to [email protected] for more information.

• Employees5
• Founded2019